Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC 50 s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate can be used for the research of celiac disease and infection .
In Vitro
Larazotide acetate (1-100 μM; 5 d) affects Vero cell growth. Larazotide acetate (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC 50 s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells. Larazotide acetate (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: Vero cell line Concentration: 1-100 μM Incubation Time: 5 days Result: Inhibited Vero cell growth with an CC 50 value of 82.5 μM.
In Vivo
Larazotide acetate (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: HLA-HCD4/DQ8 double transgenic miceDosage: 250 μg Administration: Intraperitoneal injection; 250 μg twice a week for 7 weeks Result: Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.
